
Systemic sclerosis (SSc) involves vasculopathy, immune dysregulation, and fibrosis, but the causal links between vascular injury and persistent fibroblast activation remain incompletely resolved. This focused narrative review examines apelin/APJ, milk fat globule–EGF factor 8 (MFG-E8), extracellular ATP/P2Y2, and kaempferol-associated redox modulation. Human SSc observations associate reduced apelin and MFG-E8 with disease features. Separate experiments in cultured fibroblasts and SSc-related mouse models support inhibition of TGF-β/Smad responses by apelin/APJ, restraint of latent TGF-β activation by MFG-E8, and ATP/P2Y2-dependent inflammatory and collagen responses. Kaempferol reduces oxidative injury and fibrosis-related outcomes in experimental systems; its dependence on AhR–Nrf2 signaling in SSc has not been established. APJ agonist studies in non-SSc pulmonary arterial hypertension models provide additional pharmacological context but do not establish efficacy in SSc. We propose a testable loss-and-gain model in which diminished protective signals and increased injury-associated signaling may jointly favor fibrosis. Direct interactions among all four pathways, their temporal ordering, and the causal contribution of vasculopathy to their combined alteration remain unproven. The review distinguishes human observations, SSc-related experiments, evidence from other conditions, and hypotheses, and identifies experiments needed to test the integrated model.
Systemic sclerosis (SSc) combines fibrosis, vasculopathy, and immune dysregulation, but how abnormalities across cellular compartments integrate remains incompletely understood. Reduced FLI1 expression has been reported in several SSc-relevant compartments, through inherited, epigenetic, and signaling-dependent mechanisms demonstrated in specific settings. Experimental perturbation reveals lineage-dependent reprogramming: fibroblasts acquire profibrotic features, endothelial cells lose vascular homeostatic identity, epithelial perturbation produces activation and tolerance-related abnormalities, and B-lineage loss alters development and subset distribution, with dendritic-cell and myeloid findings providing supporting evidence. Lineage-targeted loss demonstrates phenotypic capacity, partial Fli1 reduction sensitizes to additional injury, and combined Klf5/Fli1 insufficiency supports cooperative susceptibility. These states may converge on fibrotic, vascular, and immune disease modules, although the complete network has not been reconstructed and human organ tropism remains unexplained. FLI1 is therefore best viewed as a multicellular susceptibility and phenotype-shaping factor whose effects depend on lineage, dosage, context, and cooperating abnormalities.
Systemic sclerosis (SSc) is a clinically distinct autoimmune connective tissue disease characterized by immune dysregulation, vasculopathy, and excessive fibrosis. Monocytes and macrophages (Mo/Mφ) contribute to these processes through heterogeneous tissue-dependent states that are not sufficiently represented by a binary M1/M2 framework. Human blood and tissue studies, including recent single-cell and spatial analyses, have repeatedly identified hybrid activated monocytes and monocyte-derived macrophages associated with skin or lung involvement. Classical studies have established several Mo/Mφ-linked profibrotic mechanisms in SSc, including the secretion of cytokines, chemokines, and growth factors; organization of macrophage–stromal signaling niches; production and remodeling of the extracellular matrix; monocyte plasticity toward vascular and mesenchymal lineages; and defective efferocytosis and resolution. Upstream of these effector outputs, transcriptional, epigenetic, and metabolic programs are increasingly recognized as key regulators. As one example relevant to Mo/Mφ differentiation, we have focused on interferon regulatory factor 8 (IRF8), showing reduced IRF8 expression in circulating monocytes from diffuse cutaneous SSc associated with skin fibrosis. Experimentally, IRF8 silencing and myeloid-specific Irf8 deletion promote profibrotic features; however, the functional direction of IRF8 across lineages and tissues remains incompletely defined. Several established and emerging SSc therapeutic strategies are thought to act at least in part on the Mo/Mφ compartment, although direct SSc-derived cellular evidence remains limited. This review synthesizes Mo/Mφ diversity and effector functions in SSc and outlines therapeutic implications, highlighting the need for lineage- and tissue-resolved profiling of Mo/Mφ and mechanistic dissection of their upstream programs as a foundation for rational therapeutic strategies in SSc.
Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) are clinically and biologically distinct entities, yet research in both fields increasingly examines how genetic susceptibility may interact with environmental and metabolic exposures over the life course [...]
With their success in the treatment of various malignancies, immune checkpoint inhibitors (ICIs) are quickly being established as a critical component of treatment plans in oncology. However, due to concerns regarding autoimmune flares and immune-related adverse events, patients with autoimmune disease have historically been excluded from clinical trials. While research has been slowly incorporating those with autoimmune disease, research focusing on some autoimmune diseases such as systemic sclerosis is still lacking. This scoping review aimed to characterize the safety and outcomes of immune checkpoint inhibitor therapy in patients with systemic sclerosis. A literature search conducted through PubMed, Semantic Scholar, and OpenAlex was performed through June 2026 in accordance with the PRISMA-Scoping Review guidelines. Available evidence regarding the safety of ICI therapy in patients with pre-existing systemic sclerosis remains limited and heterogeneous. Autoimmune flares and immune-related adverse events, including severe complications, have been reported, and the available data are insufficient to establish the safety or tolerability of ICIs in this population. Further prospective studies are needed to better characterize outcomes and identify factors associated with increased risk.